Effects of Eggshell Membrane and Curcumin Extract Supplementation, Separately or Combined, on Recovery From Intense Exercise

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexMale
Age18-40
SponsorESM Technologies, LLC

About this trial

Eggshell membrane and Curcumin supplementation prior to intense exercise may reduce inflammation, muscle and joint pain, and promote recovery. This proof-of-concept study will examine how ingestion of specially formulated versions of these nutrients affects recovery from intense exercise.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Age 18 to 40 at the time of consent.

Healthy and recreationally active.

Ability to comply with study procedures.

Agree to refrain from alcohol intake and use of non-steroidal anti-inflammatory (NSAIDS), aspirin, and other over-the-counter pain medications for 48 hours prior to and after completion of each testing session.

Disqualifiers

No recent history of exercise training

An orthopedic limitation that would prevent the ability to perform the exercise intervention.

Participants who currently smoke cigarettes.

Known allergies to eggs, sulfur, or curcumin.

Trial design

Design model

Parallel

Treatments tested in this trial

  • NEM® brand eggshell membrane powder

    Dietary supplement

    500 mg/day of NEM® brand eggshell membrane powder in a single #0 capsule.

  • curQ+® brand highly absorbable curcumin

    Dietary supplement

    2,860 mg/day of curQ+® brand highly absorbable curcumin in a single 10 Oval softgel.

  • EM Placebo

    Dietary supplement

    500 mg/day of psyllium husk fiber powder in a single #0 capsule.

  • Curc Placebo

    Dietary supplement

    2,860 mg/day of coconut oil/polysorbate blend in a single 10 Oval softgel.

  • NEM® plus curQ+® combination

    Dietary supplement

    500 mg/day of NEM® brand eggshell membrane powder in a single #0 capsule PLUS 2,860 mg/day of curQ+® brand highly absorbable curcumin in a single 10 Oval softgel.

Treatment groups

60 Participants
are divided into 4 treatment groups
Group A: Active, EMExperimental treatment 2 interventions
Group B: Active, curcExperimental treatment 2 interventions
Group C: PlaceboPlacebo comparator 2 interventions
Group D: Active, EM+CurcExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

VAS Muscle Soreness Rating

Changes in Visual Analog Scale (VAS) ratings of muscle soreness (rated from zero to 100 mm) from baseline following intense exercise. The higher the rating, the more muscle soreness so negative changes in VAS would equate to improvement.

Time frame
2 weeks

Secondary outcomes

1

Urinary CTX-II

Changes in urinary CTX-II biomarker from baseline following intense exercise.

Time frame
2 weeks
2

Muscle Damage

Changes in markers of muscle enzyme efflux/damage (CK, LDH) from baseline following intense exercise.

Time frame
2 weeks
3

Exercise Performance

Changes in exercise performance (strength, muscular endurance, peak aerobic capacity) from baseline following intense exercise.

Time frame
2 weeks
4

Inflammation Biomarkers

Changes in markers of inflammation (TNFα, interleukin (IL) cytokines (IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10) from baseline following intense exercise.

Time frame
2 weeks

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

ESM Technologies, LLC

Lead sponsor

Exercise & Sport Nutrition Lab, Texas A&M University

Collaborator